WESTON, Fla. – About 10% to 20% of breast cancers are called “triple negative,” meaning they don’t respond to hormone therapies and other medications.
Although this can make triple-negative breast cancer more deadly, Dr. Thomas Samuel, an oncologist at Cleveland Clinic Weston, said a recent study found subtypes of the disease that respond differently to treatment.
“This tells us that if you have any of these certain subtypes, they may need less therapy than we would normally recommend. In other words, not all triple negative breast cancers are the same and they don’t all need to be treated the same. It really should be. a breakdown of what triple negative cancer it is and then adapt the treatment to that diagnosis, ”he said.
Samuel said research needs to focus on molecular and genetic testing to find more treatment options for these subtypes of triple negative breast cancer.
And data from a prospective study continue to show that patients with some blood cancers have a low response to the COVID-19 vaccine.
The latest prospective study found that less than 40% of patients with Chronic Lymphocytic Leukemia, or CLL, had an adequate antibody response after the second dose of the vaccine.
Other studies have shown a low response rate for people with multiple myeloma.
Despite the findings, researchers said patients still need to be vaccinated to achieve some level of protection against the virus and continue to follow precautionary guidelines.
Copyright 2021 by WPLG Local10.com – All rights reserved.